Log In
Print
BCIQ
Print
Print this Print this
 

subcutaneous veltuzumab, veltuzumab (hA20, IMMU-106)

  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionHumanized anti-CD20 mAb
Molecular Target CD20
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today